Sullivan Aids Amgen On $315M Kidney Drugmaker Buy
Amgen Inc. has acquired KAI Pharmaceuticals Inc., which is developing a drug to combat kidney disease, from its venture capital backers for $315 million, the California-based biotech company said Tuesday....To view the full article, register now.
Already a subscriber? Click here to view full article